Emergent BioSolutions | EBS - Należności Handlowe





Należności Handlowe Zmiana Data
Acadia Pharmaceuticals USD 148.23M 8.79M 2025-12
Akebia Therapeutics USD 47.03M 19.19M 2025-12
ALKERMES USD 334.02M 21.08M 2025-12
Alnylam Pharmaceuticals USD 777.57M 187.2M 2025-12
Amarin USD 126.83M 477K 2025-12
ANI Pharmaceuticals USD 281.08M 28.46M 2025-12
BioMarin Pharmaceutical USD 908.21M 117.95M 2025-12
Coherus Biosciences USD 18.42M 232.08M 2025-12
Emergent BioSolutions USD 290.1M 134.2M 2023-06
Exelixis USD 286.92M 24.38M 2025-12
Glaxosmithkline GBP 10.45B 707.81M 2025-12
Heron Therapeutics USD 89.59M 8.54M 2025-12
Ionis Pharmaceuticals USD 66M 41.39M 2025-12
Ironwood Pharmaceuticals USD 81.89M 5.68M 2024-12
Lexicon Pharmaceuticals USD 2.38M 50K 2025-12
Lonza CHF 1.78B 55M 2025-12
Merck USD 12.12B 596M 2025-09
Moderna USD 184M 862M 2025-12
Myriad Genetics USD 115.3M 2.7M 2025-12
Nektar Therapeutics USD 1.78M 1.12M 2025-12
Neurocrine Biosciences USD 686.8M 41.2M 2025-12
Pacira USD 124.07M 8.8M 2025-12
Pfizer USD 18.12B 2.02B 2025-09
PTC Therapeutics USD 181.62M 21.45M 2025-12
Sanofi EUR 397M 100M 2025-12
Sarepta Therapeutics USD 398.23M 2.49M 2025-12
United Therapeutics USD 350.2M 52.5M 2025-12
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12
Xoma USD 14.78M 4.96M 2024-06